Regeneron commits $500 million for new venture capital fund

16 April 2024
regeneron_big

A new investment fund has been launched by Regeneron (Nasdaq: REGN), with half a billion dollars to spend on biotech innovation.

The upswing in investor interest forms part of a broader industry trend, with an increasing number of companies opting to  list on a stock exchange this year.

On the venture capital front, Regeneron’s move adds to existing funds that have been active in recent months, including ORI Capital, which has  raised $260 million to spend on biotech, as well as Scion Life Sciences, which  has $310 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology